<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004442</url>
  </required_header>
  <id_info>
    <org_study_id>199/13442</org_study_id>
    <secondary_id>CHMC-C-FDR000995</secondary_id>
    <nct_id>NCT00004442</nct_id>
  </id_info>
  <brief_title>Study of Bile Acids in Patients With Peroxisomal Disorders</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine the effectiveness of oral bile acid therapy with cholic acid,
      chenodeoxycholic acid, and ursodeoxycholic acid in patients with peroxisomal disorders
      involving impaired primary bile acid synthesis.

      II. Determine whether suppression of synthesis of atypical bile acids and enrichment of bile
      acid pool with this regimen is effective in treating this patient population and improving
      quality of life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: Patients receive oral cholic acid and oral chenodeoxycholic acid on day 1.
      On day 4, patients receive oral cholic and ursodeoxycholic acids. Patients are assessed at 3
      and 6 months for liver function response, neurologic status, and nutritional status.

      Patients receive treatment until disease progression or unacceptable toxic effects are
      observed.

      Completion date provided represents the completion date of the grant per OOPD records
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <completion_date>April 1999</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Infantile Refsum's Disease</condition>
  <condition>Zellweger Syndrome</condition>
  <condition>Bifunctional Enzyme Deficiency</condition>
  <condition>Adrenoleukodystrophy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chenodeoxycholic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholic acid</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ursodiol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Biochemically proven peroxisomal disorder, including:

          -  Zellweger syndrome

          -  Pseudo-Zellweger syndrome

          -  Neonatal adrenoleukodystrophy

          -  Bifunctional enzyme deficiency

          -  Infantile Refsum's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Setchell</last_name>
    <role>Study Chair</role>
    <affiliation>Children's Hospital Medical Center, Cincinnati</affiliation>
  </overall_official>
  <verification_date>November 2000</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 1999</study_first_submitted>
  <study_first_submitted_qc>October 18, 1999</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 1999</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>Zellweger syndrome</keyword>
  <keyword>adrenoleukodystrophy</keyword>
  <keyword>bifunctional enzyme deficiency</keyword>
  <keyword>inborn errors of metabolism</keyword>
  <keyword>infantile Refsum's disease</keyword>
  <keyword>peroxisomal disorders</keyword>
  <keyword>pseudo-Zellweger syndrome</keyword>
  <keyword>rare disease</keyword>
  <keyword>sphingolipidoses</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Peroxisomal Disorders</mesh_term>
    <mesh_term>Zellweger Syndrome</mesh_term>
    <mesh_term>Refsum Disease, Infantile</mesh_term>
    <mesh_term>Refsum Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
    <mesh_term>Cholic Acids</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

